D-0088-2024 Class III Ongoing
FDA drug recall D-0088-2024 was initiated by AbbVie Inc. on Oct 17, 2023 and is designated Class III. Reason for recall: Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose. The recall status is ongoing. Affected quantity: 864 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 15, 2023
- Initiation Date
- Oct 17, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 864 cartons
Product description
Synthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg), 100-count bottle, Rx Only AbbVie Inc. North Chicago, IL 60064, U.S.A. NDC 0074-7068-11
Reason for recall
Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose.
Distribution pattern
Distributed in the US. No government or foreign consignees.
Code information
Lot # 1187435 exp date: 02/2024
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0088-2024
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026